nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.0415	0.0624	CbGbCtD
Sorafenib—ABCC4—Zidovudine—acquired immunodeficiency syndrome	0.0199	0.0299	CbGbCtD
Sorafenib—ABCC4—Lamivudine—acquired immunodeficiency syndrome	0.0154	0.0231	CbGbCtD
Sorafenib—ABCC2—Indinavir—acquired immunodeficiency syndrome	0.014	0.0211	CbGbCtD
Sorafenib—ABCC2—Ritonavir—acquired immunodeficiency syndrome	0.0123	0.0185	CbGbCtD
Sorafenib—ABCC2—Saquinavir—acquired immunodeficiency syndrome	0.0123	0.0185	CbGbCtD
Sorafenib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0123	0.0185	CbGbCtD
Sorafenib—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0122	0.0183	CbGbCtD
Sorafenib—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0114	0.0172	CbGbCtD
Sorafenib—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0114	0.0172	CbGbCtD
Sorafenib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0111	0.0167	CbGbCtD
Sorafenib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0111	0.0167	CbGbCtD
Sorafenib—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0109	0.0163	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0109	0.0163	CbGbCtD
Sorafenib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0107	0.0161	CbGbCtD
Sorafenib—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0103	0.0155	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.00937	0.0141	CbGbCtD
Sorafenib—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.00937	0.0141	CbGbCtD
Sorafenib—ABCC2—Lamivudine—acquired immunodeficiency syndrome	0.00914	0.0137	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0091	0.0137	CbGbCtD
Sorafenib—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0091	0.0137	CbGbCtD
Sorafenib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.009	0.0135	CbGbCtD
Sorafenib—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.00866	0.013	CbGbCtD
Sorafenib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00826	0.0124	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.00823	0.0124	CbGbCtD
Sorafenib—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.00823	0.0124	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.00823	0.0124	CbGbCtD
Sorafenib—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.00823	0.0124	CbGbCtD
Sorafenib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.00814	0.0122	CbGbCtD
Sorafenib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.00814	0.0122	CbGbCtD
Sorafenib—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.00783	0.0118	CbGbCtD
Sorafenib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.00783	0.0118	CbGbCtD
Sorafenib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.00783	0.0118	CbGbCtD
Sorafenib—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.00772	0.0116	CbGbCtD
Sorafenib—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.00726	0.0109	CbGbCtD
Sorafenib—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.00713	0.0107	CbGbCtD
Sorafenib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.00703	0.0106	CbGbCtD
Sorafenib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.00682	0.0103	CbGbCtD
Sorafenib—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0067	0.0101	CbGbCtD
Sorafenib—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0067	0.0101	CbGbCtD
Sorafenib—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.00657	0.00988	CbGbCtD
Sorafenib—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.00657	0.00988	CbGbCtD
Sorafenib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.00642	0.00966	CbGbCtD
Sorafenib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00617	0.00928	CbGbCtD
Sorafenib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00617	0.00928	CbGbCtD
Sorafenib—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00606	0.00911	CbGbCtD
Sorafenib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00604	0.00908	CbGbCtD
Sorafenib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00604	0.00908	CbGbCtD
Sorafenib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00593	0.00892	CbGbCtD
Sorafenib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00593	0.00892	CbGbCtD
Sorafenib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00587	0.00883	CbGbCtD
Sorafenib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00586	0.00881	CbGbCtD
Sorafenib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00569	0.00855	CbGbCtD
Sorafenib—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00567	0.00853	CbGbCtD
Sorafenib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.00552	0.0083	CbGbCtD
Sorafenib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.00552	0.0083	CbGbCtD
Sorafenib—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0055	0.00828	CbGbCtD
Sorafenib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00546	0.00821	CbGbCtD
Sorafenib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00546	0.00821	CbGbCtD
Sorafenib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0053	0.00797	CbGbCtD
Sorafenib—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00508	0.00764	CbGbCtD
Sorafenib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00499	0.00751	CbGbCtD
Sorafenib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00499	0.00751	CbGbCtD
Sorafenib—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00498	0.00749	CbGbCtD
Sorafenib—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00498	0.00749	CbGbCtD
Sorafenib—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00477	0.00718	CbGbCtD
Sorafenib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00471	0.00709	CbGbCtD
Sorafenib—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00459	0.00691	CbGbCtD
Sorafenib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00458	0.00688	CbGbCtD
Sorafenib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00457	0.00688	CbGbCtD
Sorafenib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00444	0.00668	CbGbCtD
Sorafenib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00431	0.00648	CbGbCtD
Sorafenib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00418	0.00629	CbGbCtD
Sorafenib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00414	0.00622	CbGbCtD
Sorafenib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00414	0.00622	CbGbCtD
Sorafenib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00402	0.00604	CbGbCtD
Sorafenib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00402	0.00604	CbGbCtD
Sorafenib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00397	0.00597	CbGbCtD
Sorafenib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00385	0.00579	CbGbCtD
Sorafenib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00378	0.00569	CbGbCtD
Sorafenib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00378	0.00569	CbGbCtD
Sorafenib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00373	0.00562	CbGbCtD
Sorafenib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00351	0.00528	CbGbCtD
Sorafenib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00351	0.00528	CbGbCtD
Sorafenib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00318	0.00477	CbGbCtD
Sorafenib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00318	0.00477	CbGbCtD
Sorafenib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00298	0.00448	CbGbCtD
Sorafenib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00274	0.00412	CbGbCtD
Sorafenib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00266	0.004	CbGbCtD
Sorafenib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00241	0.00362	CbGbCtD
Sorafenib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00241	0.00362	CbGbCtD
Sorafenib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00231	0.00347	CbGbCtD
Sorafenib—Vismodegib—ALB—acquired immunodeficiency syndrome	0.000552	1	CrCbGaD
Sorafenib—MKNK2—blood—acquired immunodeficiency syndrome	0.00034	0.00339	CbGeAlD
Sorafenib—MAP3K7—bone marrow—acquired immunodeficiency syndrome	0.00034	0.00338	CbGeAlD
Sorafenib—AURKC—lymph node—acquired immunodeficiency syndrome	0.00034	0.00338	CbGeAlD
Sorafenib—MAP3K7—spinal cord—acquired immunodeficiency syndrome	0.000338	0.00337	CbGeAlD
Sorafenib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000337	0.00336	CbGeAlD
Sorafenib—MKNK1—blood—acquired immunodeficiency syndrome	0.000336	0.00334	CbGeAlD
Sorafenib—RET—blood—acquired immunodeficiency syndrome	0.000332	0.0033	CbGeAlD
Sorafenib—FLT4—lung—acquired immunodeficiency syndrome	0.000329	0.00328	CbGeAlD
Sorafenib—MKNK2—bone marrow—acquired immunodeficiency syndrome	0.000329	0.00328	CbGeAlD
Sorafenib—MKNK2—spinal cord—acquired immunodeficiency syndrome	0.000328	0.00326	CbGeAlD
Sorafenib—EPHA6—brain—acquired immunodeficiency syndrome	0.000325	0.00324	CbGeAlD
Sorafenib—MAP3K7—vagina—acquired immunodeficiency syndrome	0.000325	0.00324	CbGeAlD
Sorafenib—FGFR1—lung—acquired immunodeficiency syndrome	0.000325	0.00324	CbGeAlD
Sorafenib—MKNK1—bone marrow—acquired immunodeficiency syndrome	0.000325	0.00324	CbGeAlD
Sorafenib—MKNK1—spinal cord—acquired immunodeficiency syndrome	0.000324	0.00322	CbGeAlD
Sorafenib—RALBP1—digestive system—acquired immunodeficiency syndrome	0.000322	0.00321	CbGeAlD
Sorafenib—RET—spinal cord—acquired immunodeficiency syndrome	0.00032	0.00318	CbGeAlD
Sorafenib—CSF1R—skin of body—acquired immunodeficiency syndrome	0.000316	0.00315	CbGeAlD
Sorafenib—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000316	0.00314	CbGeAlD
Sorafenib—MKNK2—vagina—acquired immunodeficiency syndrome	0.000315	0.00314	CbGeAlD
Sorafenib—MKNK1—vagina—acquired immunodeficiency syndrome	0.000311	0.0031	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—acquired immunodeficiency syndrome	0.00031	0.00309	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—acquired immunodeficiency syndrome	0.000309	0.00307	CbGeAlD
Sorafenib—ZAK—brain—acquired immunodeficiency syndrome	0.000308	0.00307	CbGeAlD
Sorafenib—MAP3K7—lung—acquired immunodeficiency syndrome	0.000308	0.00306	CbGeAlD
Sorafenib—RALBP1—blood—acquired immunodeficiency syndrome	0.000307	0.00306	CbGeAlD
Sorafenib—FLT1—digestive system—acquired immunodeficiency syndrome	0.000307	0.00305	CbGeAlD
Sorafenib—RAF1—digestive system—acquired immunodeficiency syndrome	0.000305	0.00304	CbGeAlD
Sorafenib—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000304	0.00303	CbGeAlD
Sorafenib—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.000303	0.00301	CbGeAlD
Sorafenib—HIPK3—brain—acquired immunodeficiency syndrome	0.000302	0.00301	CbGeAlD
Sorafenib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.0003	0.00298	CbGeAlD
Sorafenib—MKNK2—lung—acquired immunodeficiency syndrome	0.000298	0.00297	CbGeAlD
Sorafenib—ZAK—lymph node—acquired immunodeficiency syndrome	0.000298	0.00297	CbGeAlD
Sorafenib—RALBP1—bone marrow—acquired immunodeficiency syndrome	0.000297	0.00296	CbGeAlD
Sorafenib—RALBP1—spinal cord—acquired immunodeficiency syndrome	0.000296	0.00295	CbGeAlD
Sorafenib—MAP3K19—brain—acquired immunodeficiency syndrome	0.000296	0.00294	CbGeAlD
Sorafenib—MKNK1—lung—acquired immunodeficiency syndrome	0.000294	0.00293	CbGeAlD
Sorafenib—STK10—lymphoid tissue—acquired immunodeficiency syndrome	0.000294	0.00293	CbGeAlD
Sorafenib—FLT1—blood—acquired immunodeficiency syndrome	0.000292	0.00291	CbGeAlD
Sorafenib—HIPK3—lymph node—acquired immunodeficiency syndrome	0.000292	0.0029	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—acquired immunodeficiency syndrome	0.000291	0.0029	CbGeAlD
Sorafenib—RAF1—blood—acquired immunodeficiency syndrome	0.00029	0.00289	CbGeAlD
Sorafenib—STK10—digestive system—acquired immunodeficiency syndrome	0.00029	0.00289	CbGeAlD
Sorafenib—EPHB6—blood—acquired immunodeficiency syndrome	0.000289	0.00288	CbGeAlD
Sorafenib—PDGFRA—digestive system—acquired immunodeficiency syndrome	0.000287	0.00286	CbGeAlD
Sorafenib—KIT—skin of body—acquired immunodeficiency syndrome	0.000287	0.00286	CbGeAlD
Sorafenib—RALBP1—vagina—acquired immunodeficiency syndrome	0.000285	0.00283	CbGeAlD
Sorafenib—TIE1—brain—acquired immunodeficiency syndrome	0.000282	0.00281	CbGeAlD
Sorafenib—FLT1—spinal cord—acquired immunodeficiency syndrome	0.000281	0.0028	CbGeAlD
Sorafenib—RAF1—bone marrow—acquired immunodeficiency syndrome	0.000281	0.0028	CbGeAlD
Sorafenib—PDGFRB—skin of body—acquired immunodeficiency syndrome	0.000281	0.00279	CbGeAlD
Sorafenib—RAF1—spinal cord—acquired immunodeficiency syndrome	0.00028	0.00279	CbGeAlD
Sorafenib—EPHB6—spinal cord—acquired immunodeficiency syndrome	0.000278	0.00277	CbGeAlD
Sorafenib—STK10—blood—acquired immunodeficiency syndrome	0.000277	0.00275	CbGeAlD
Sorafenib—MKNK2—nervous system—acquired immunodeficiency syndrome	0.000276	0.00275	CbGeAlD
Sorafenib—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.000274	0.00273	CbGeAlD
Sorafenib—PDGFRA—blood—acquired immunodeficiency syndrome	0.000274	0.00273	CbGeAlD
Sorafenib—TIE1—lymph node—acquired immunodeficiency syndrome	0.000273	0.00271	CbGeAlD
Sorafenib—MKNK1—nervous system—acquired immunodeficiency syndrome	0.000273	0.00271	CbGeAlD
Sorafenib—FLT1—vagina—acquired immunodeficiency syndrome	0.000271	0.0027	CbGeAlD
Sorafenib—BRAF—brain—acquired immunodeficiency syndrome	0.000271	0.00269	CbGeAlD
Sorafenib—RET—nervous system—acquired immunodeficiency syndrome	0.000269	0.00268	CbGeAlD
Sorafenib—RALBP1—lung—acquired immunodeficiency syndrome	0.000269	0.00268	CbGeAlD
Sorafenib—RAF1—vagina—acquired immunodeficiency syndrome	0.000269	0.00268	CbGeAlD
Sorafenib—EPHB6—vagina—acquired immunodeficiency syndrome	0.000268	0.00267	CbGeAlD
Sorafenib—STK10—bone marrow—acquired immunodeficiency syndrome	0.000268	0.00266	CbGeAlD
Sorafenib—MKNK2—central nervous system—acquired immunodeficiency syndrome	0.000266	0.00265	CbGeAlD
Sorafenib—PDGFRA—spinal cord—acquired immunodeficiency syndrome	0.000264	0.00263	CbGeAlD
Sorafenib—MKNK1—central nervous system—acquired immunodeficiency syndrome	0.000262	0.00261	CbGeAlD
Sorafenib—KDR—lymphoid tissue—acquired immunodeficiency syndrome	0.000262	0.00261	CbGeAlD
Sorafenib—BRAF—lymph node—acquired immunodeficiency syndrome	0.000261	0.0026	CbGeAlD
Sorafenib—UGT1A1—blood—acquired immunodeficiency syndrome	0.000261	0.0026	CbGeAlD
Sorafenib—RET—central nervous system—acquired immunodeficiency syndrome	0.000259	0.00258	CbGeAlD
Sorafenib—KDR—digestive system—acquired immunodeficiency syndrome	0.000259	0.00258	CbGeAlD
Sorafenib—EPHX2—brain—acquired immunodeficiency syndrome	0.000259	0.00257	CbGeAlD
Sorafenib—STK10—vagina—acquired immunodeficiency syndrome	0.000256	0.00255	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—acquired immunodeficiency syndrome	0.000256	0.00255	CbGeAlD
Sorafenib—FLT1—lung—acquired immunodeficiency syndrome	0.000256	0.00255	CbGeAlD
Sorafenib—RAF1—lung—acquired immunodeficiency syndrome	0.000255	0.00254	CbGeAlD
Sorafenib—PDGFRA—vagina—acquired immunodeficiency syndrome	0.000254	0.00253	CbGeAlD
Sorafenib—EPHB6—lung—acquired immunodeficiency syndrome	0.000253	0.00252	CbGeAlD
Sorafenib—CSF1R—digestive system—acquired immunodeficiency syndrome	0.000253	0.00252	CbGeAlD
Sorafenib—EPHX2—lymph node—acquired immunodeficiency syndrome	0.00025	0.00249	CbGeAlD
Sorafenib—RALBP1—nervous system—acquired immunodeficiency syndrome	0.000249	0.00248	CbGeAlD
Sorafenib—FLT3—lymph node—acquired immunodeficiency syndrome	0.000248	0.00247	CbGeAlD
Sorafenib—MAP2K5—blood—acquired immunodeficiency syndrome	0.000247	0.00246	CbGeAlD
Sorafenib—KDR—blood—acquired immunodeficiency syndrome	0.000247	0.00246	CbGeAlD
Sorafenib—STK10—lung—acquired immunodeficiency syndrome	0.000242	0.00241	CbGeAlD
Sorafenib—CSF1R—blood—acquired immunodeficiency syndrome	0.000241	0.0024	CbGeAlD
Sorafenib—RALBP1—central nervous system—acquired immunodeficiency syndrome	0.00024	0.00239	CbGeAlD
Sorafenib—PDGFRA—lung—acquired immunodeficiency syndrome	0.00024	0.00239	CbGeAlD
Sorafenib—KDR—bone marrow—acquired immunodeficiency syndrome	0.000239	0.00238	CbGeAlD
Sorafenib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	0.000238	0.00237	CbGeAlD
Sorafenib—KDR—spinal cord—acquired immunodeficiency syndrome	0.000238	0.00237	CbGeAlD
Sorafenib—FLT1—nervous system—acquired immunodeficiency syndrome	0.000237	0.00236	CbGeAlD
Sorafenib—RAF1—nervous system—acquired immunodeficiency syndrome	0.000236	0.00235	CbGeAlD
Sorafenib—EPHB6—nervous system—acquired immunodeficiency syndrome	0.000234	0.00233	CbGeAlD
Sorafenib—CSF1R—bone marrow—acquired immunodeficiency syndrome	0.000233	0.00232	CbGeAlD
Sorafenib—FLT4—brain—acquired immunodeficiency syndrome	0.000233	0.00232	CbGeAlD
Sorafenib—KIT—lymphoid tissue—acquired immunodeficiency syndrome	0.000233	0.00232	CbGeAlD
Sorafenib—CSF1R—spinal cord—acquired immunodeficiency syndrome	0.000232	0.00231	CbGeAlD
Sorafenib—FGFR1—brain—acquired immunodeficiency syndrome	0.00023	0.00229	CbGeAlD
Sorafenib—KIT—digestive system—acquired immunodeficiency syndrome	0.00023	0.00229	CbGeAlD
Sorafenib—KDR—vagina—acquired immunodeficiency syndrome	0.000229	0.00228	CbGeAlD
Sorafenib—MAP2K5—vagina—acquired immunodeficiency syndrome	0.000229	0.00228	CbGeAlD
Sorafenib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000228	0.00227	CbGeAlD
Sorafenib—FLT1—central nervous system—acquired immunodeficiency syndrome	0.000228	0.00227	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	0.000227	0.00226	CbGeAlD
Sorafenib—RAF1—central nervous system—acquired immunodeficiency syndrome	0.000227	0.00226	CbGeAlD
Sorafenib—EPHB6—central nervous system—acquired immunodeficiency syndrome	0.000226	0.00225	CbGeAlD
Sorafenib—FLT4—lymph node—acquired immunodeficiency syndrome	0.000225	0.00224	CbGeAlD
Sorafenib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000225	0.00224	CbGeAlD
Sorafenib—STK10—nervous system—acquired immunodeficiency syndrome	0.000225	0.00224	CbGeAlD
Sorafenib—PDGFRB—digestive system—acquired immunodeficiency syndrome	0.000224	0.00223	CbGeAlD
Sorafenib—CSF1R—vagina—acquired immunodeficiency syndrome	0.000223	0.00222	CbGeAlD
Sorafenib—FGFR1—lymph node—acquired immunodeficiency syndrome	0.000222	0.00221	CbGeAlD
Sorafenib—PDGFRA—nervous system—acquired immunodeficiency syndrome	0.000222	0.00221	CbGeAlD
Sorafenib—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000222	0.00221	CbGeAlD
Sorafenib—KIT—blood—acquired immunodeficiency syndrome	0.000219	0.00218	CbGeAlD
Sorafenib—MAP3K7—brain—acquired immunodeficiency syndrome	0.000218	0.00217	CbGeAlD
Sorafenib—KDR—lung—acquired immunodeficiency syndrome	0.000216	0.00216	CbGeAlD
Sorafenib—MAP2K5—lung—acquired immunodeficiency syndrome	0.000216	0.00216	CbGeAlD
Sorafenib—STK10—central nervous system—acquired immunodeficiency syndrome	0.000216	0.00215	CbGeAlD
Sorafenib—PDGFRA—central nervous system—acquired immunodeficiency syndrome	0.000214	0.00213	CbGeAlD
Sorafenib—PDGFRB—blood—acquired immunodeficiency syndrome	0.000214	0.00213	CbGeAlD
Sorafenib—KIT—bone marrow—acquired immunodeficiency syndrome	0.000212	0.00211	CbGeAlD
Sorafenib—CSF1R—lung—acquired immunodeficiency syndrome	0.000211	0.0021	CbGeAlD
Sorafenib—MKNK2—brain—acquired immunodeficiency syndrome	0.000211	0.0021	CbGeAlD
Sorafenib—KIT—spinal cord—acquired immunodeficiency syndrome	0.000211	0.0021	CbGeAlD
Sorafenib—MAP3K7—lymph node—acquired immunodeficiency syndrome	0.00021	0.00209	CbGeAlD
Sorafenib—MKNK1—brain—acquired immunodeficiency syndrome	0.000208	0.00207	CbGeAlD
Sorafenib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	0.000207	0.00206	CbGeAlD
Sorafenib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	0.000206	0.00205	CbGeAlD
Sorafenib—RET—brain—acquired immunodeficiency syndrome	0.000206	0.00205	CbGeAlD
Sorafenib—MKNK2—lymph node—acquired immunodeficiency syndrome	0.000204	0.00203	CbGeAlD
Sorafenib—KIT—vagina—acquired immunodeficiency syndrome	0.000203	0.00202	CbGeAlD
Sorafenib—MKNK1—lymph node—acquired immunodeficiency syndrome	0.000201	0.002	CbGeAlD
Sorafenib—MAP2K5—nervous system—acquired immunodeficiency syndrome	0.0002	0.002	CbGeAlD
Sorafenib—KDR—nervous system—acquired immunodeficiency syndrome	0.0002	0.002	CbGeAlD
Sorafenib—RET—lymph node—acquired immunodeficiency syndrome	0.000199	0.00198	CbGeAlD
Sorafenib—PDGFRB—vagina—acquired immunodeficiency syndrome	0.000198	0.00197	CbGeAlD
Sorafenib—CSF1R—nervous system—acquired immunodeficiency syndrome	0.000196	0.00195	CbGeAlD
Sorafenib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	0.000193	0.00192	CbGeAlD
Sorafenib—KDR—central nervous system—acquired immunodeficiency syndrome	0.000193	0.00192	CbGeAlD
Sorafenib—KIT—lung—acquired immunodeficiency syndrome	0.000192	0.00191	CbGeAlD
Sorafenib—RALBP1—brain—acquired immunodeficiency syndrome	0.000191	0.0019	CbGeAlD
Sorafenib—CSF1R—central nervous system—acquired immunodeficiency syndrome	0.000188	0.00188	CbGeAlD
Sorafenib—PDGFRB—lung—acquired immunodeficiency syndrome	0.000187	0.00187	CbGeAlD
Sorafenib—RALBP1—lymph node—acquired immunodeficiency syndrome	0.000184	0.00183	CbGeAlD
Sorafenib—FLT1—brain—acquired immunodeficiency syndrome	0.000181	0.0018	CbGeAlD
Sorafenib—RAF1—brain—acquired immunodeficiency syndrome	0.00018	0.00179	CbGeAlD
Sorafenib—EPHB6—brain—acquired immunodeficiency syndrome	0.000179	0.00178	CbGeAlD
Sorafenib—ABCC4—digestive system—acquired immunodeficiency syndrome	0.000179	0.00178	CbGeAlD
Sorafenib—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000178	0.00177	CbGeAlD
Sorafenib—KIT—nervous system—acquired immunodeficiency syndrome	0.000178	0.00177	CbGeAlD
Sorafenib—FLT1—lymph node—acquired immunodeficiency syndrome	0.000175	0.00174	CbGeAlD
Sorafenib—RAF1—lymph node—acquired immunodeficiency syndrome	0.000174	0.00173	CbGeAlD
Sorafenib—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000174	0.00173	CbGeAlD
Sorafenib—PDGFRB—nervous system—acquired immunodeficiency syndrome	0.000174	0.00173	CbGeAlD
Sorafenib—EPHB6—lymph node—acquired immunodeficiency syndrome	0.000173	0.00172	CbGeAlD
Sorafenib—ABCC2—digestive system—acquired immunodeficiency syndrome	0.000173	0.00172	CbGeAlD
Sorafenib—STK10—brain—acquired immunodeficiency syndrome	0.000172	0.00171	CbGeAlD
Sorafenib—KIT—central nervous system—acquired immunodeficiency syndrome	0.000171	0.0017	CbGeAlD
Sorafenib—ABCC4—blood—acquired immunodeficiency syndrome	0.00017	0.00169	CbGeAlD
Sorafenib—PDGFRA—brain—acquired immunodeficiency syndrome	0.00017	0.00169	CbGeAlD
Sorafenib—HTR2B—blood—acquired immunodeficiency syndrome	0.000169	0.00169	CbGeAlD
Sorafenib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	0.000167	0.00166	CbGeAlD
Sorafenib—STK10—lymph node—acquired immunodeficiency syndrome	0.000166	0.00165	CbGeAlD
Sorafenib—ABCC2—blood—acquired immunodeficiency syndrome	0.000165	0.00164	CbGeAlD
Sorafenib—ABCC4—bone marrow—acquired immunodeficiency syndrome	0.000165	0.00164	CbGeAlD
Sorafenib—PDGFRA—lymph node—acquired immunodeficiency syndrome	0.000164	0.00163	CbGeAlD
Sorafenib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000162	0.00161	CbGeAlD
Sorafenib—HTR2B—vagina—acquired immunodeficiency syndrome	0.000157	0.00156	CbGeAlD
Sorafenib—MAP2K5—brain—acquired immunodeficiency syndrome	0.000153	0.00153	CbGeAlD
Sorafenib—KDR—brain—acquired immunodeficiency syndrome	0.000153	0.00153	CbGeAlD
Sorafenib—CSF1R—brain—acquired immunodeficiency syndrome	0.00015	0.00149	CbGeAlD
Sorafenib—ABCC4—lung—acquired immunodeficiency syndrome	0.000149	0.00149	CbGeAlD
Sorafenib—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000149	0.00148	CbGeAlD
Sorafenib—HTR2B—lung—acquired immunodeficiency syndrome	0.000148	0.00148	CbGeAlD
Sorafenib—MAP2K5—lymph node—acquired immunodeficiency syndrome	0.000148	0.00147	CbGeAlD
Sorafenib—KDR—lymph node—acquired immunodeficiency syndrome	0.000148	0.00147	CbGeAlD
Sorafenib—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000146	0.00146	CbGeAlD
Sorafenib—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000145	0.00145	CbGeAlD
Sorafenib—CSF1R—lymph node—acquired immunodeficiency syndrome	0.000145	0.00144	CbGeAlD
Sorafenib—CYP2C19—blood—acquired immunodeficiency syndrome	0.000142	0.00141	CbGeAlD
Sorafenib—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000141	0.0014	CbGeAlD
Sorafenib—ABCC4—nervous system—acquired immunodeficiency syndrome	0.000138	0.00138	CbGeAlD
Sorafenib—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000137	0.00137	CbGeAlD
Sorafenib—KIT—brain—acquired immunodeficiency syndrome	0.000136	0.00135	CbGeAlD
Sorafenib—ABCC4—central nervous system—acquired immunodeficiency syndrome	0.000133	0.00132	CbGeAlD
Sorafenib—PDGFRB—brain—acquired immunodeficiency syndrome	0.000133	0.00132	CbGeAlD
Sorafenib—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000132	0.00132	CbGeAlD
Sorafenib—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000131	0.00131	CbGeAlD
Sorafenib—KIT—lymph node—acquired immunodeficiency syndrome	0.000131	0.00131	CbGeAlD
Sorafenib—PDGFRB—lymph node—acquired immunodeficiency syndrome	0.000128	0.00128	CbGeAlD
Sorafenib—CYP2C8—blood—acquired immunodeficiency syndrome	0.000124	0.00123	CbGeAlD
Sorafenib—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000121	0.00121	CbGeAlD
Sorafenib—ABCG2—blood—acquired immunodeficiency syndrome	0.00012	0.0012	CbGeAlD
Sorafenib—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000118	0.00117	CbGeAlD
Sorafenib—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000117	0.00117	CbGeAlD
Sorafenib—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000116	0.00116	CbGeAlD
Sorafenib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000116	0.00116	CbGeAlD
Sorafenib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000116	0.00115	CbGeAlD
Sorafenib—CYP1A2—blood—acquired immunodeficiency syndrome	0.000116	0.00115	CbGeAlD
Sorafenib—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000115	0.00115	CbGeAlD
Sorafenib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000115	0.00114	CbGeAlD
Sorafenib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000113	0.000622	CcSEcCtD
Sorafenib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000113	0.000622	CcSEcCtD
Sorafenib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000113	0.000621	CcSEcCtD
Sorafenib—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000113	0.000619	CcSEcCtD
Sorafenib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000618	CcSEcCtD
Sorafenib—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000617	CcSEcCtD
Sorafenib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.000617	CcSEcCtD
Sorafenib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000112	0.000617	CcSEcCtD
Sorafenib—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000616	CcSEcCtD
Sorafenib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.000616	CcSEcCtD
Sorafenib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000615	CcSEcCtD
Sorafenib—HTR2C—brain—acquired immunodeficiency syndrome	0.000112	0.00111	CbGeAlD
Sorafenib—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000112	0.000613	CcSEcCtD
Sorafenib—CYP3A5—blood—acquired immunodeficiency syndrome	0.000112	0.00111	CbGeAlD
Sorafenib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000111	0.00111	CbGeAlD
Sorafenib—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000111	0.000611	CcSEcCtD
Sorafenib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000611	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000111	0.000611	CcSEcCtD
Sorafenib—CYP2B6—blood—acquired immunodeficiency syndrome	0.000111	0.0011	CbGeAlD
Sorafenib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000111	0.000608	CcSEcCtD
Sorafenib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000111	0.000608	CcSEcCtD
Sorafenib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000607	CcSEcCtD
Sorafenib—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.00011	0.000604	CcSEcCtD
Sorafenib—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000604	CcSEcCtD
Sorafenib—CYP2C9—blood—acquired immunodeficiency syndrome	0.00011	0.00109	CbGeAlD
Sorafenib—Rash—Didanosine—acquired immunodeficiency syndrome	0.00011	0.000603	CcSEcCtD
Sorafenib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.000602	CcSEcCtD
Sorafenib—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00011	0.000602	CcSEcCtD
Sorafenib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00011	0.000602	CcSEcCtD
Sorafenib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.0006	CcSEcCtD
Sorafenib—Headache—Didanosine—acquired immunodeficiency syndrome	0.000109	0.000599	CcSEcCtD
Sorafenib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000598	CcSEcCtD
Sorafenib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000109	0.000597	CcSEcCtD
Sorafenib—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000109	0.000597	CcSEcCtD
Sorafenib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000108	0.000595	CcSEcCtD
Sorafenib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000108	0.000594	CcSEcCtD
Sorafenib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.000593	CcSEcCtD
Sorafenib—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000593	CcSEcCtD
Sorafenib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000592	CcSEcCtD
Sorafenib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000107	0.00059	CcSEcCtD
Sorafenib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000107	0.00059	CcSEcCtD
Sorafenib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000589	CcSEcCtD
Sorafenib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000107	0.000589	CcSEcCtD
Sorafenib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000107	0.000588	CcSEcCtD
Sorafenib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000107	0.000587	CcSEcCtD
Sorafenib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000107	0.000587	CcSEcCtD
Sorafenib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000585	CcSEcCtD
Sorafenib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000585	CcSEcCtD
Sorafenib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000106	0.000583	CcSEcCtD
Sorafenib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000583	CcSEcCtD
Sorafenib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000581	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000581	CcSEcCtD
Sorafenib—ABCC4—brain—acquired immunodeficiency syndrome	0.000106	0.00105	CbGeAlD
Sorafenib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000579	CcSEcCtD
Sorafenib—ABCG2—lung—acquired immunodeficiency syndrome	0.000105	0.00105	CbGeAlD
Sorafenib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000105	0.000578	CcSEcCtD
Sorafenib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000578	CcSEcCtD
Sorafenib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000578	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000577	CcSEcCtD
Sorafenib—HTR2B—brain—acquired immunodeficiency syndrome	0.000105	0.00105	CbGeAlD
Sorafenib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000577	CcSEcCtD
Sorafenib—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000576	CcSEcCtD
Sorafenib—Pain—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000574	CcSEcCtD
Sorafenib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000574	CcSEcCtD
Sorafenib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.000573	CcSEcCtD
Sorafenib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000572	CcSEcCtD
Sorafenib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000571	CcSEcCtD
Sorafenib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.00057	CcSEcCtD
Sorafenib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.00057	CcSEcCtD
Sorafenib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000104	0.00057	CcSEcCtD
Sorafenib—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000103	0.00103	CbGeAlD
Sorafenib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000103	0.000568	CcSEcCtD
Sorafenib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000103	0.000568	CcSEcCtD
Sorafenib—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000566	CcSEcCtD
Sorafenib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000565	CcSEcCtD
Sorafenib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000565	CcSEcCtD
Sorafenib—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000103	0.00102	CbGeAlD
Sorafenib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000563	CcSEcCtD
Sorafenib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000563	CcSEcCtD
Sorafenib—ABCC4—lymph node—acquired immunodeficiency syndrome	0.000102	0.00102	CbGeAlD
Sorafenib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000102	0.000559	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000559	CcSEcCtD
Sorafenib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000558	CcSEcCtD
Sorafenib—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000102	0.00101	CbGeAlD
Sorafenib—CYP1A2—lung—acquired immunodeficiency syndrome	0.000101	0.00101	CbGeAlD
Sorafenib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000555	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000552	CcSEcCtD
Sorafenib—Shock—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.000552	CcSEcCtD
Sorafenib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.0001	0.000551	CcSEcCtD
Sorafenib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000551	CcSEcCtD
Sorafenib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000551	CcSEcCtD
Sorafenib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.0001	0.00055	CcSEcCtD
Sorafenib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.00055	CcSEcCtD
Sorafenib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	9.99e-05	0.000549	CcSEcCtD
Sorafenib—Dizziness—Stavudine—acquired immunodeficiency syndrome	9.99e-05	0.000549	CcSEcCtD
Sorafenib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	9.98e-05	0.000549	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	9.96e-05	0.000547	CcSEcCtD
Sorafenib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	9.95e-05	0.000546	CcSEcCtD
Sorafenib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	9.95e-05	0.000546	CcSEcCtD
Sorafenib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	9.91e-05	0.000545	CcSEcCtD
Sorafenib—ABCC2—lymph node—acquired immunodeficiency syndrome	9.88e-05	0.000984	CbGeAlD
Sorafenib—Constipation—Efavirenz—acquired immunodeficiency syndrome	9.86e-05	0.000542	CcSEcCtD
Sorafenib—Pain—Efavirenz—acquired immunodeficiency syndrome	9.86e-05	0.000542	CcSEcCtD
Sorafenib—Rash—Nevirapine—acquired immunodeficiency syndrome	9.86e-05	0.000542	CcSEcCtD
Sorafenib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	9.85e-05	0.000541	CcSEcCtD
Sorafenib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.000541	CcSEcCtD
Sorafenib—Dizziness—Abacavir—acquired immunodeficiency syndrome	9.84e-05	0.000541	CcSEcCtD
Sorafenib—Headache—Nevirapine—acquired immunodeficiency syndrome	9.8e-05	0.000538	CcSEcCtD
Sorafenib—CYP3A5—lung—acquired immunodeficiency syndrome	9.78e-05	0.000973	CbGeAlD
Sorafenib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	9.78e-05	0.000537	CcSEcCtD
Sorafenib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	9.78e-05	0.000537	CcSEcCtD
Sorafenib—Infection—Saquinavir—acquired immunodeficiency syndrome	9.76e-05	0.000536	CcSEcCtD
Sorafenib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	9.73e-05	0.000535	CcSEcCtD
Sorafenib—CYP2B6—lung—acquired immunodeficiency syndrome	9.72e-05	0.000967	CbGeAlD
Sorafenib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	9.72e-05	0.000534	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	9.71e-05	0.000533	CcSEcCtD
Sorafenib—Urticaria—Indinavir—acquired immunodeficiency syndrome	9.7e-05	0.000533	CcSEcCtD
Sorafenib—Shock—Saquinavir—acquired immunodeficiency syndrome	9.66e-05	0.000531	CcSEcCtD
Sorafenib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	9.65e-05	0.00053	CcSEcCtD
Sorafenib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	9.65e-05	0.00053	CcSEcCtD
Sorafenib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	9.63e-05	0.000529	CcSEcCtD
Sorafenib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	9.63e-05	0.000529	CcSEcCtD
Sorafenib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	9.62e-05	0.000528	CcSEcCtD
Sorafenib—Vomiting—Stavudine—acquired immunodeficiency syndrome	9.6e-05	0.000528	CcSEcCtD
Sorafenib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	9.59e-05	0.000527	CcSEcCtD
Sorafenib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	9.56e-05	0.000525	CcSEcCtD
Sorafenib—Rash—Nelfinavir—acquired immunodeficiency syndrome	9.55e-05	0.000525	CcSEcCtD
Sorafenib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	9.54e-05	0.000524	CcSEcCtD
Sorafenib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	9.54e-05	0.000524	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	9.53e-05	0.000524	CcSEcCtD
Sorafenib—Rash—Stavudine—acquired immunodeficiency syndrome	9.52e-05	0.000523	CcSEcCtD
Sorafenib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	9.52e-05	0.000523	CcSEcCtD
Sorafenib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	9.51e-05	0.000523	CcSEcCtD
Sorafenib—Headache—Nelfinavir—acquired immunodeficiency syndrome	9.49e-05	0.000521	CcSEcCtD
Sorafenib—Headache—Stavudine—acquired immunodeficiency syndrome	9.46e-05	0.00052	CcSEcCtD
Sorafenib—Vomiting—Abacavir—acquired immunodeficiency syndrome	9.46e-05	0.00052	CcSEcCtD
Sorafenib—Constipation—Delavirdine—acquired immunodeficiency syndrome	9.44e-05	0.000519	CcSEcCtD
Sorafenib—Pain—Delavirdine—acquired immunodeficiency syndrome	9.44e-05	0.000519	CcSEcCtD
Sorafenib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	9.43e-05	0.000518	CcSEcCtD
Sorafenib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	9.42e-05	0.000518	CcSEcCtD
Sorafenib—Rash—Abacavir—acquired immunodeficiency syndrome	9.38e-05	0.000515	CcSEcCtD
Sorafenib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	9.37e-05	0.000515	CcSEcCtD
Sorafenib—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	9.37e-05	0.000515	CcSEcCtD
Sorafenib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	9.36e-05	0.000514	CcSEcCtD
Sorafenib—Headache—Abacavir—acquired immunodeficiency syndrome	9.32e-05	0.000512	CcSEcCtD
Sorafenib—Infection—Lamivudine—acquired immunodeficiency syndrome	9.31e-05	0.000512	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	9.3e-05	0.000511	CcSEcCtD
Sorafenib—Nausea—Nevirapine—acquired immunodeficiency syndrome	9.29e-05	0.000511	CcSEcCtD
Sorafenib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	9.29e-05	0.00051	CcSEcCtD
Sorafenib—Shock—Lamivudine—acquired immunodeficiency syndrome	9.22e-05	0.000507	CcSEcCtD
Sorafenib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	9.19e-05	0.000505	CcSEcCtD
Sorafenib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	9.18e-05	0.000504	CcSEcCtD
Sorafenib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	9.16e-05	0.000503	CcSEcCtD
Sorafenib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	9.12e-05	0.000501	CcSEcCtD
Sorafenib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	9.12e-05	0.000501	CcSEcCtD
Sorafenib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.1e-05	0.0005	CcSEcCtD
Sorafenib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.0005	CcSEcCtD
Sorafenib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.03e-05	0.000496	CcSEcCtD
Sorafenib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9e-05	0.000494	CcSEcCtD
Sorafenib—CYP2B6—nervous system—acquired immunodeficiency syndrome	9e-05	0.000896	CbGeAlD
Sorafenib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	9e-05	0.000494	CcSEcCtD
Sorafenib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	8.98e-05	0.000494	CcSEcCtD
Sorafenib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	8.98e-05	0.000494	CcSEcCtD
Sorafenib—Nausea—Stavudine—acquired immunodeficiency syndrome	8.97e-05	0.000493	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	8.95e-05	0.000492	CcSEcCtD
Sorafenib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	8.93e-05	0.000491	CcSEcCtD
Sorafenib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	8.87e-05	0.000487	CcSEcCtD
Sorafenib—ABCB1—retina—acquired immunodeficiency syndrome	8.86e-05	0.000882	CbGeAlD
Sorafenib—Nausea—Abacavir—acquired immunodeficiency syndrome	8.84e-05	0.000486	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	8.81e-05	0.000484	CcSEcCtD
Sorafenib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	8.8e-05	0.000483	CcSEcCtD
Sorafenib—CYP3A4—digestive system—acquired immunodeficiency syndrome	8.79e-05	0.000875	CbGeAlD
Sorafenib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	8.77e-05	0.000482	CcSEcCtD
Sorafenib—Asthenia—Indinavir—acquired immunodeficiency syndrome	8.76e-05	0.000481	CcSEcCtD
Sorafenib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000481	CcSEcCtD
Sorafenib—Pain—Ritonavir—acquired immunodeficiency syndrome	8.73e-05	0.00048	CcSEcCtD
Sorafenib—Constipation—Ritonavir—acquired immunodeficiency syndrome	8.73e-05	0.00048	CcSEcCtD
Sorafenib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	8.73e-05	0.000479	CcSEcCtD
Sorafenib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	8.73e-05	0.000479	CcSEcCtD
Sorafenib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	8.68e-05	0.000477	CcSEcCtD
Sorafenib—CYP2B6—central nervous system—acquired immunodeficiency syndrome	8.66e-05	0.000863	CbGeAlD
Sorafenib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	8.65e-05	0.000475	CcSEcCtD
Sorafenib—CYP2D6—digestive system—acquired immunodeficiency syndrome	8.65e-05	0.000861	CbGeAlD
Sorafenib—Pruritus—Indinavir—acquired immunodeficiency syndrome	8.64e-05	0.000475	CcSEcCtD
Sorafenib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	8.54e-05	0.000469	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	8.54e-05	0.000469	CcSEcCtD
Sorafenib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	8.5e-05	0.000467	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	8.48e-05	0.000466	CcSEcCtD
Sorafenib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	8.47e-05	0.000465	CcSEcCtD
Sorafenib—Constipation—Saquinavir—acquired immunodeficiency syndrome	8.4e-05	0.000462	CcSEcCtD
Sorafenib—Pain—Saquinavir—acquired immunodeficiency syndrome	8.4e-05	0.000462	CcSEcCtD
Sorafenib—CYP3A4—blood—acquired immunodeficiency syndrome	8.37e-05	0.000833	CbGeAlD
Sorafenib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000459	CcSEcCtD
Sorafenib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	8.35e-05	0.000459	CcSEcCtD
Sorafenib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	8.35e-05	0.000459	CcSEcCtD
Sorafenib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	8.35e-05	0.000459	CcSEcCtD
Sorafenib—Rash—Zidovudine—acquired immunodeficiency syndrome	8.28e-05	0.000455	CcSEcCtD
Sorafenib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.28e-05	0.000455	CcSEcCtD
Sorafenib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.27e-05	0.000454	CcSEcCtD
Sorafenib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.25e-05	0.000453	CcSEcCtD
Sorafenib—CYP2D6—blood—acquired immunodeficiency syndrome	8.24e-05	0.00082	CbGeAlD
Sorafenib—Headache—Zidovudine—acquired immunodeficiency syndrome	8.22e-05	0.000452	CcSEcCtD
Sorafenib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.16e-05	0.000448	CcSEcCtD
Sorafenib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.15e-05	0.000448	CcSEcCtD
Sorafenib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	8.13e-05	0.000447	CcSEcCtD
Sorafenib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	8.11e-05	0.000445	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.09e-05	0.000445	CcSEcCtD
Sorafenib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.08e-05	0.000444	CcSEcCtD
Sorafenib—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.07e-05	0.000444	CcSEcCtD
Sorafenib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.07e-05	0.000443	CcSEcCtD
Sorafenib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	8.07e-05	0.000443	CcSEcCtD
Sorafenib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.03e-05	0.000441	CcSEcCtD
Sorafenib—Pain—Lamivudine—acquired immunodeficiency syndrome	8.01e-05	0.00044	CcSEcCtD
Sorafenib—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.01e-05	0.00044	CcSEcCtD
Sorafenib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	7.92e-05	0.000435	CcSEcCtD
Sorafenib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	7.89e-05	0.000434	CcSEcCtD
Sorafenib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	7.81e-05	0.000429	CcSEcCtD
Sorafenib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	7.8e-05	0.000429	CcSEcCtD
Sorafenib—Nausea—Zidovudine—acquired immunodeficiency syndrome	7.8e-05	0.000428	CcSEcCtD
Sorafenib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	7.77e-05	0.000427	CcSEcCtD
Sorafenib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	7.77e-05	0.000427	CcSEcCtD
Sorafenib—Vomiting—Indinavir—acquired immunodeficiency syndrome	7.76e-05	0.000427	CcSEcCtD
Sorafenib—Rash—Indinavir—acquired immunodeficiency syndrome	7.7e-05	0.000423	CcSEcCtD
Sorafenib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	7.69e-05	0.000423	CcSEcCtD
Sorafenib—CYP2C8—brain—acquired immunodeficiency syndrome	7.67e-05	0.000763	CbGeAlD
Sorafenib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	7.66e-05	0.000421	CcSEcCtD
Sorafenib—Headache—Indinavir—acquired immunodeficiency syndrome	7.65e-05	0.00042	CcSEcCtD
Sorafenib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	7.63e-05	0.000419	CcSEcCtD
Sorafenib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	7.55e-05	0.000415	CcSEcCtD
Sorafenib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	7.52e-05	0.000413	CcSEcCtD
Sorafenib—ABCG2—brain—acquired immunodeficiency syndrome	7.46e-05	0.000742	CbGeAlD
Sorafenib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	7.44e-05	0.000409	CcSEcCtD
Sorafenib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	7.41e-05	0.000407	CcSEcCtD
Sorafenib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.41e-05	0.000407	CcSEcCtD
Sorafenib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.33e-05	0.000403	CcSEcCtD
Sorafenib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.32e-05	0.000402	CcSEcCtD
Sorafenib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.3e-05	0.000401	CcSEcCtD
Sorafenib—Rash—Efavirenz—acquired immunodeficiency syndrome	7.27e-05	0.0004	CcSEcCtD
Sorafenib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.27e-05	0.000399	CcSEcCtD
Sorafenib—Nausea—Indinavir—acquired immunodeficiency syndrome	7.25e-05	0.000398	CcSEcCtD
Sorafenib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	7.24e-05	0.000398	CcSEcCtD
Sorafenib—Headache—Efavirenz—acquired immunodeficiency syndrome	7.23e-05	0.000397	CcSEcCtD
Sorafenib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.22e-05	0.000397	CcSEcCtD
Sorafenib—ABCG2—lymph node—acquired immunodeficiency syndrome	7.2e-05	0.000717	CbGeAlD
Sorafenib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.05e-05	0.000387	CcSEcCtD
Sorafenib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.02e-05	0.000386	CcSEcCtD
Sorafenib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	6.98e-05	0.000384	CcSEcCtD
Sorafenib—Rash—Delavirdine—acquired immunodeficiency syndrome	6.96e-05	0.000382	CcSEcCtD
Sorafenib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	6.95e-05	0.000382	CcSEcCtD
Sorafenib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	6.95e-05	0.000382	CcSEcCtD
Sorafenib—Headache—Delavirdine—acquired immunodeficiency syndrome	6.91e-05	0.00038	CcSEcCtD
Sorafenib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	6.9e-05	0.000379	CcSEcCtD
Sorafenib—CYP2B6—brain—acquired immunodeficiency syndrome	6.88e-05	0.000685	CbGeAlD
Sorafenib—Nausea—Efavirenz—acquired immunodeficiency syndrome	6.85e-05	0.000376	CcSEcCtD
Sorafenib—CYP3A4—nervous system—acquired immunodeficiency syndrome	6.79e-05	0.000677	CbGeAlD
Sorafenib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000371	CcSEcCtD
Sorafenib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	6.72e-05	0.000369	CcSEcCtD
Sorafenib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	6.72e-05	0.000369	CcSEcCtD
Sorafenib—CYP2D6—nervous system—acquired immunodeficiency syndrome	6.69e-05	0.000666	CbGeAlD
Sorafenib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	6.63e-05	0.000364	CcSEcCtD
Sorafenib—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.56e-05	0.00036	CcSEcCtD
Sorafenib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	6.54e-05	0.000651	CbGeAlD
Sorafenib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.5e-05	0.000357	CcSEcCtD
Sorafenib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.49e-05	0.000357	CcSEcCtD
Sorafenib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	6.44e-05	0.000641	CbGeAlD
Sorafenib—Rash—Ritonavir—acquired immunodeficiency syndrome	6.44e-05	0.000354	CcSEcCtD
Sorafenib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.43e-05	0.000353	CcSEcCtD
Sorafenib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.41e-05	0.000352	CcSEcCtD
Sorafenib—Headache—Ritonavir—acquired immunodeficiency syndrome	6.39e-05	0.000351	CcSEcCtD
Sorafenib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	6.3e-05	0.000627	CbGeAlD
Sorafenib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.25e-05	0.000343	CcSEcCtD
Sorafenib—ABCB1—digestive system—acquired immunodeficiency syndrome	6.22e-05	0.000619	CbGeAlD
Sorafenib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.2e-05	0.00034	CcSEcCtD
Sorafenib—Rash—Saquinavir—acquired immunodeficiency syndrome	6.19e-05	0.00034	CcSEcCtD
Sorafenib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.19e-05	0.00034	CcSEcCtD
Sorafenib—Headache—Saquinavir—acquired immunodeficiency syndrome	6.15e-05	0.000338	CcSEcCtD
Sorafenib—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.06e-05	0.000333	CcSEcCtD
Sorafenib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.96e-05	0.000327	CcSEcCtD
Sorafenib—ABCB1—blood—acquired immunodeficiency syndrome	5.92e-05	0.00059	CbGeAlD
Sorafenib—Rash—Lamivudine—acquired immunodeficiency syndrome	5.91e-05	0.000325	CcSEcCtD
Sorafenib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.9e-05	0.000324	CcSEcCtD
Sorafenib—Headache—Lamivudine—acquired immunodeficiency syndrome	5.87e-05	0.000323	CcSEcCtD
Sorafenib—Nausea—Saquinavir—acquired immunodeficiency syndrome	5.84e-05	0.000321	CcSEcCtD
Sorafenib—ABCB1—bone marrow—acquired immunodeficiency syndrome	5.73e-05	0.000571	CbGeAlD
Sorafenib—ABCB1—spinal cord—acquired immunodeficiency syndrome	5.71e-05	0.000568	CbGeAlD
Sorafenib—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.57e-05	0.000306	CcSEcCtD
Sorafenib—ABCB1—vagina—acquired immunodeficiency syndrome	5.49e-05	0.000547	CbGeAlD
Sorafenib—ABCB1—lung—acquired immunodeficiency syndrome	5.19e-05	0.000517	CbGeAlD
Sorafenib—CYP2D6—brain—acquired immunodeficiency syndrome	5.11e-05	0.000509	CbGeAlD
Sorafenib—ABCB1—nervous system—acquired immunodeficiency syndrome	4.81e-05	0.000479	CbGeAlD
Sorafenib—ABCB1—central nervous system—acquired immunodeficiency syndrome	4.63e-05	0.000461	CbGeAlD
Sorafenib—ABCB1—brain—acquired immunodeficiency syndrome	3.68e-05	0.000366	CbGeAlD
Sorafenib—ABCB1—lymph node—acquired immunodeficiency syndrome	3.55e-05	0.000354	CbGeAlD
Sorafenib—BRAF—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.45e-05	0.000278	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.44e-05	0.000278	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.44e-05	0.000278	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD8A—acquired immunodeficiency syndrome	1.44e-05	0.000277	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CSF2—acquired immunodeficiency syndrome	1.44e-05	0.000277	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—ALB—acquired immunodeficiency syndrome	1.44e-05	0.000277	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD79A—acquired immunodeficiency syndrome	1.44e-05	0.000276	CbGpPWpGaD
Sorafenib—RAF1—Disease—CXCR4—acquired immunodeficiency syndrome	1.43e-05	0.000275	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.43e-05	0.000274	CbGpPWpGaD
Sorafenib—KIT—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.43e-05	0.000274	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.42e-05	0.000274	CbGpPWpGaD
Sorafenib—BRAF—Disease—CCR5—acquired immunodeficiency syndrome	1.41e-05	0.000272	CbGpPWpGaD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.41e-05	0.000271	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.4e-05	0.000269	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.4e-05	0.000269	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-B—acquired immunodeficiency syndrome	1.39e-05	0.000268	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—IL2—acquired immunodeficiency syndrome	1.39e-05	0.000267	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-B—acquired immunodeficiency syndrome	1.39e-05	0.000267	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.38e-05	0.000265	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.38e-05	0.000264	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.38e-05	0.000264	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.37e-05	0.000263	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.37e-05	0.000263	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.37e-05	0.000263	CbGpPWpGaD
Sorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.36e-05	0.000262	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.36e-05	0.000261	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.35e-05	0.00026	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.35e-05	0.00026	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.35e-05	0.000259	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.35e-05	0.000259	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.34e-05	0.000258	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.33e-05	0.000255	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.32e-05	0.000255	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.32e-05	0.000255	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.32e-05	0.000254	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.32e-05	0.000253	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.32e-05	0.000253	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.32e-05	0.000253	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.32e-05	0.000253	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD40LG—acquired immunodeficiency syndrome	1.32e-05	0.000253	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.3e-05	0.000251	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD8A—acquired immunodeficiency syndrome	1.3e-05	0.00025	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CSF2—acquired immunodeficiency syndrome	1.3e-05	0.00025	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.29e-05	0.000248	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.29e-05	0.000248	CbGpPWpGaD
Sorafenib—KIT—Disease—CCR5—acquired immunodeficiency syndrome	1.29e-05	0.000248	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.28e-05	0.000247	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.27e-05	0.000244	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.27e-05	0.000244	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.27e-05	0.000243	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.27e-05	0.000243	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.26e-05	0.000242	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.26e-05	0.000242	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.25e-05	0.000241	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-B—acquired immunodeficiency syndrome	1.25e-05	0.00024	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.25e-05	0.00024	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.25e-05	0.00024	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.25e-05	0.00024	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.25e-05	0.00024	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.25e-05	0.000239	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.25e-05	0.000239	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.24e-05	0.000239	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.23e-05	0.000237	CbGpPWpGaD
Sorafenib—CDK7—Disease—CD4—acquired immunodeficiency syndrome	1.23e-05	0.000236	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—IL6—acquired immunodeficiency syndrome	1.22e-05	0.000235	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.22e-05	0.000235	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CCR5—acquired immunodeficiency syndrome	1.22e-05	0.000235	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CCR5—acquired immunodeficiency syndrome	1.22e-05	0.000234	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.22e-05	0.000234	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.21e-05	0.000232	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.19e-05	0.000229	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.19e-05	0.000229	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.19e-05	0.000228	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.18e-05	0.000226	CbGpPWpGaD
Sorafenib—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.18e-05	0.000226	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD40LG—acquired immunodeficiency syndrome	1.17e-05	0.000225	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000225	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.16e-05	0.000224	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.16e-05	0.000223	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD8A—acquired immunodeficiency syndrome	1.16e-05	0.000223	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CSF2—acquired immunodeficiency syndrome	1.16e-05	0.000223	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.14e-05	0.00022	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.14e-05	0.000219	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.12e-05	0.000216	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.12e-05	0.000216	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000216	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-B—acquired immunodeficiency syndrome	1.11e-05	0.000214	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.11e-05	0.000214	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.11e-05	0.000213	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.1e-05	0.000212	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.1e-05	0.000212	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.1e-05	0.000211	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CCR5—acquired immunodeficiency syndrome	1.1e-05	0.000211	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.1e-05	0.000211	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.09e-05	0.00021	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.09e-05	0.00021	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.09e-05	0.000209	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.08e-05	0.000208	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.08e-05	0.000208	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.08e-05	0.000208	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.07e-05	0.000206	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.07e-05	0.000206	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.07e-05	0.000206	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.06e-05	0.000204	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.02e-05	0.000196	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.02e-05	0.000195	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.01e-05	0.000194	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IFNG—acquired immunodeficiency syndrome	1.01e-05	0.000193	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1e-05	0.000193	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1e-05	0.000192	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1e-05	0.000192	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1e-05	0.000192	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1e-05	0.000192	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1e-05	0.000192	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.91e-06	0.00019	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.86e-06	0.00019	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.86e-06	0.00019	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—IL6—acquired immunodeficiency syndrome	9.81e-06	0.000189	CbGpPWpGaD
Sorafenib—RAF1—Disease—CCR5—acquired immunodeficiency syndrome	9.79e-06	0.000188	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	9.73e-06	0.000187	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD4—acquired immunodeficiency syndrome	9.71e-06	0.000187	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.5e-06	0.000183	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.47e-06	0.000182	CbGpPWpGaD
Sorafenib—MKNK1—Disease—IL6—acquired immunodeficiency syndrome	9.41e-06	0.000181	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.36e-06	0.00018	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.33e-06	0.000179	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.18e-06	0.000176	CbGpPWpGaD
Sorafenib—KIT—Immune System—IFNG—acquired immunodeficiency syndrome	9.07e-06	0.000174	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IFNG—acquired immunodeficiency syndrome	9.07e-06	0.000174	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—IL6—acquired immunodeficiency syndrome	9.02e-06	0.000173	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.02e-06	0.000173	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.02e-06	0.000173	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL2—acquired immunodeficiency syndrome	8.94e-06	0.000172	CbGpPWpGaD
Sorafenib—BRAF—Disease—CD4—acquired immunodeficiency syndrome	8.88e-06	0.000171	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD4—acquired immunodeficiency syndrome	8.76e-06	0.000168	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD4—acquired immunodeficiency syndrome	8.76e-06	0.000168	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	8.75e-06	0.000168	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—IL6—acquired immunodeficiency syndrome	8.74e-06	0.000168	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TNF—acquired immunodeficiency syndrome	8.67e-06	0.000167	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.63e-06	0.000166	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.63e-06	0.000166	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IFNG—acquired immunodeficiency syndrome	8.61e-06	0.000165	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IFNG—acquired immunodeficiency syndrome	8.58e-06	0.000165	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.56e-06	0.000164	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.54e-06	0.000164	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.54e-06	0.000164	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.41e-06	0.000162	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD4—acquired immunodeficiency syndrome	8.31e-06	0.00016	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD4—acquired immunodeficiency syndrome	8.29e-06	0.000159	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	8.27e-06	0.000159	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.14e-06	0.000156	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.13e-06	0.000156	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.13e-06	0.000156	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.09e-06	0.000155	CbGpPWpGaD
Sorafenib—KIT—Disease—CD4—acquired immunodeficiency syndrome	8.09e-06	0.000155	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL2—acquired immunodeficiency syndrome	8.06e-06	0.000155	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL2—acquired immunodeficiency syndrome	8.06e-06	0.000155	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.02e-06	0.000154	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.96e-06	0.000153	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.9e-06	0.000152	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	7.73e-06	0.000149	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.72e-06	0.000148	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.7e-06	0.000148	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.69e-06	0.000148	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CD4—acquired immunodeficiency syndrome	7.67e-06	0.000148	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CD4—acquired immunodeficiency syndrome	7.65e-06	0.000147	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL2—acquired immunodeficiency syndrome	7.65e-06	0.000147	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL2—acquired immunodeficiency syndrome	7.63e-06	0.000147	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.61e-06	0.000146	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.49e-06	0.000144	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	7.47e-06	0.000144	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.33e-06	0.000141	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.17e-06	0.000138	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.1e-06	0.000136	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—acquired immunodeficiency syndrome	7e-06	0.000135	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.93e-06	0.000133	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	6.9e-06	0.000133	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.89e-06	0.000133	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—acquired immunodeficiency syndrome	6.89e-06	0.000132	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	6.87e-06	0.000132	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.85e-06	0.000132	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.72e-06	0.000129	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.7e-06	0.000129	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—acquired immunodeficiency syndrome	6.66e-06	0.000128	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—acquired immunodeficiency syndrome	6.63e-06	0.000128	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.59e-06	0.000127	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.57e-06	0.000126	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.47e-06	0.000124	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.37e-06	0.000122	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.34e-06	0.000122	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.18e-06	0.000119	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—acquired immunodeficiency syndrome	6.15e-06	0.000118	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—acquired immunodeficiency syndrome	6.12e-06	0.000118	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	6e-06	0.000115	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—acquired immunodeficiency syndrome	6e-06	0.000115	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.94e-06	0.000114	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.92e-06	0.000114	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.88e-06	0.000113	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.79e-06	0.000111	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.78e-06	0.000111	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.78e-06	0.000111	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.72e-06	0.00011	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—acquired immunodeficiency syndrome	5.25e-06	0.000101	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.21e-06	0.0001	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.21e-06	0.0001	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	5.09e-06	9.79e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	5.05e-06	9.71e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.94e-06	9.5e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.94e-06	9.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.93e-06	9.48e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—acquired immunodeficiency syndrome	4.8e-06	9.24e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—acquired immunodeficiency syndrome	4.74e-06	9.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—acquired immunodeficiency syndrome	4.74e-06	9.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—acquired immunodeficiency syndrome	4.49e-06	8.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—acquired immunodeficiency syndrome	4.48e-06	8.62e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.44e-06	8.54e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—acquired immunodeficiency syndrome	4.37e-06	8.41e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.24e-06	8.14e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.22e-06	8.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—acquired immunodeficiency syndrome	4.15e-06	7.98e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—acquired immunodeficiency syndrome	4.14e-06	7.96e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.05e-06	7.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	4.04e-06	7.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.96e-06	7.61e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.95e-06	7.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.94e-06	7.57e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	3.73e-06	7.18e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	3.73e-06	7.17e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	3.65e-06	7.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—acquired immunodeficiency syndrome	3.6e-06	6.92e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.42e-06	6.57e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.4e-06	6.54e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.4e-06	6.53e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.36e-06	6.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—acquired immunodeficiency syndrome	3.32e-06	6.39e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	3.16e-06	6.08e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.06e-06	5.89e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.06e-06	5.89e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.91e-06	5.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.9e-06	5.57e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	2.82e-06	5.42e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.75e-06	5.29e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.61e-06	5.02e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.6e-06	4.99e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.57e-06	4.95e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.49e-06	4.79e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.33e-06	4.47e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	2.2e-06	4.23e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.01e-06	3.86e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.7e-06	3.26e-05	CbGpPWpGaD
